Physician profile
Robert Deluca
NPI 1295729739
$6,963.46
in general payments reported to CMS, 2019-2025
42 companies · $938 in 2025
The $938 reported for 2025 was more than what 85% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $610 · 2020: $729 · 2021: $1,363 · 2022: $1,368 · 2023: $1,138 · 2024: $818 · 2025: $938.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,894.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,893.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $1,475.94 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Abbvie INC. | $715.15 | 2020-2025 | Qulipta, Ubrelvy, Vraylar |
| Lilly USA, LLC | $614.49 | 2019-2025 | Mounjaro, Zepbound, Trulicity |
| Novo Nordisk INC | $427.87 | 2019-2025 | Ozempic, Rybelsus |
| Astellas Pharma US INC | $394.17 | 2019-2025 | Veozah, Myrbetriq |
| Pfizer INC. | $348.87 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $266.17 | 2021-2025 | Jardiance |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $237.30 | 2022-2025 | Caplyta |
| Merck Sharp & Dohme LLC | $195.61 | 2019-2023 | Belsomra, Steglatro, Verquvo |
| Novartis Pharmaceuticals Corporation | $192.18 | 2019-2023 | |
| Abbott Laboratories | $178.33 | 2021-2025 | Freestyle Libre |
| Glaxosmithkline, LLC. | $174.45 | 2019-2025 | Trelegy Ellipta, Shingrix |
| Gm Pharmaceuticals, INC. | $154.57 | 2023 | Vanacof |
| Allergan, INC. | $137.96 | 2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $134.91 | 2022-2025 |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Deluca listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.